Physician profile
Daniel Borkert
NPI 1285651042
$9,265.59
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $1,280 · 2021: $1,629 · 2022: $1,551 · 2023: $1,444 · 2024: $1,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,700.73 | 2019-2024 | Vraylar, Linzess, Ubrelvy |
| Janssen Pharmaceuticals, INC | $824.29 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $608.82 | 2019-2024 | Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $524.92 | 2023-2024 | Qelbree, Qelbree |
| Lilly USA, LLC | $516.70 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $513.14 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $478.69 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $411.30 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $405.49 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.32 | 2019-2024 | Jardiance |
| Viiv Healthcare Company | $247.46 | 2022-2024 | Apretude |
| Esperion Therapeutics, INC. | $229.53 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $183.39 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $181.54 | 2019-2023 | |
| Gilead Sciences, INC. | $171.96 | 2019-2024 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Borkert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.